| Mr Daniel P Collins, PT | |
|
230 N Main St, Suite 5, Rutland, VT 05701-2416 | |
| (802) 773-4900 | |
| (802) 774-5600 |
| Full Name | Mr Daniel P Collins |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 25 Years |
| Location | 230 N Main St, Rutland, Vermont |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053348730 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 0400003307 (Vermont) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Springfield Hospital Inc. | 6507760337 | 30 |
News Archive
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.
Ms. Little's seemingly minor medical problem -; she had the least dangerous form of skin cancer -; racked up big bills because it involved three doctors from specialties that are among the highest compensated in medicine, and it was done on the grounds of a hospital.
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.
The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women around the world and achieve the global targets set.
Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business.
› Verified 8 days ago
| Provider Name | Springfield Hospital Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1780657783 PECOS PAC ID: 6507760337 Enrollment ID: O20040130000327 |
News Archive
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.
Ms. Little's seemingly minor medical problem -; she had the least dangerous form of skin cancer -; racked up big bills because it involved three doctors from specialties that are among the highest compensated in medicine, and it was done on the grounds of a hospital.
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.
The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women around the world and achieve the global targets set.
Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business.
› Verified 8 days ago
| Provider Name | Springfield Hospital Inc. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1033225875 PECOS PAC ID: 6507760337 Enrollment ID: O20040421000503 |
News Archive
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.
Ms. Little's seemingly minor medical problem -; she had the least dangerous form of skin cancer -; racked up big bills because it involved three doctors from specialties that are among the highest compensated in medicine, and it was done on the grounds of a hospital.
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.
The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women around the world and achieve the global targets set.
Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Daniel P Collins, PT 230 N Main St, Suite 5, Rutland, VT 05701-2416 Ph: (802) 773-4900 | Mr Daniel P Collins, PT 230 N Main St, Suite 5, Rutland, VT 05701-2416 Ph: (802) 773-4900 |
News Archive
Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the close of its $16 million Series D round of financing. Current investors Caxton Advantage Life Sciences Fund LP and Sanderling Venture Partners co-led the round. In addition, the Series D structure grants certain current investors the option to invest an additional $4 million in this financing round in the future.
Ms. Little's seemingly minor medical problem -; she had the least dangerous form of skin cancer -; racked up big bills because it involved three doctors from specialties that are among the highest compensated in medicine, and it was done on the grounds of a hospital.
With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.
The Lancet women and cardiovascular disease Commission outlines 10 ambitious recommendations to improve health outcomes for millions of women around the world and achieve the global targets set.
Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business.
› Verified 8 days ago
Joseph M Myers, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 46 Nichols St, Rutland, VT 05701 Phone: 802-775-2941 | |
Elizabeth G Bullock, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9 Haywood Ave, Rutland, VT 05701 Phone: 802-747-6428 | |
Nancy Houghton, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 7 Albert Cree Dr, Rutland, VT 05702 Phone: 802-775-0568 | |
Professional Therapy Alternatives Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 135 N Main St, Suite 3, Rutland, VT 05701 Phone: 802-747-6394 Fax: 802-747-9073 | |
Erin Marie Gordon, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 5 Albert Cree Dr, Vermont Sports Medicine Center, Rutland, VT 05701 Phone: 802-775-1300 Fax: 802-773-9300 | |
Katrina Werbinski, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 88 Park St, Rutland, VT 05701 Phone: 802-775-7612 Fax: 802-747-6993 |